To view the report in PDF format, you first need to
download the free Adobe Acrobat Viewer. The Acrobat Viewer will launch the file so that
you can see the document on your monitor and then print it. Download Adobe Acrobat.
Download the Report
|
|
October 17, 2005
 Mood Stabilisers Plus Risperidone or Placebo In The Treatment of Acute Mania Results: Young Mania Rating Scale (YMRS) scores improved rapidly with significantly greater reductions at week 1 in the risperidone group compared with the placebo group. At end-point YMRS scores decreased by 14.5 and 10.3 points in the risperidone and placebo groups, respectively. Significant improvements v. placebo (P<0.05) were noted in the risperidone group on several other clinically meaningful measures. Additionally, a post hoc analysis excluding carbamazepoine-treated patients (plasma concentrations of risperidone active moiety were 40% lower in this group) revealed significantly greater reductions (P=0.047) in YMRS scores in the risperidone group than in the placebo group. Incidence of adverse events was similar in both groups.
Conclusions: Risperidone is superior to placebo when used in combination with lithium or divalproex in acute mania.
Excerpt 
|
OPEN
MINDS